Overview
The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergology departments.
Eligibility
Inclusion Criteria:
- with hypermobile Ehlers Danlos syndrome
- with digestive disorders
- 14 years of age or older (minimum age for the MOS-SF 36 questionnaire)
- able to answer the questionnaires
- whose participation in a day hospital at Saint Vincent de Paul dedicated to the assessment of "functional digestive pain" is planned
- who do not object to the use of their health data for research purposes
Additional criteria for minors :
- No objection to the use of health data for research purposes by parents/guardians
Exclusion Criteria:
- under guardianship or curatorship
- having taken a long-term high-dose antihistamine treatment (H1 or H2) during the last
two months, according to the following thresholds :
- Desloratadine (>5 mg/jour)
- Bilastine (>20 mg/jour)
- Cetirizine (>20 mg/jour)
- Ebastine (>10 mg/jour)
- Fexofenadine (>150 mg/jour)
- Levocetirizine (>5 mg/jour)
- Loratadine (>10 mg/jour)
- Exocetiridine (5 mg/jour)
- Mizolastine (>10 mg/jour)
- Rupatadine (>10 mg/jour)
- Polaramine (>10 mg/jour)
- Oxomemazine (>2 mg/jour)
- Hydroxyzine (>25 mg/jour)
- Doxylamine (>15 mg/jour)
- Cimetidine (>200 mg/jour)
- Patients deprived of liberty, pregnant or nursing women
